Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MRF #0425 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research study is to see if a behavioral program which includes a relaxation technique and lifestyle changes can improve seizure control and well-being in epilepsy patients.
The behavioral treatment approach studied aims to help epilepsy patients discover which circumstances and behaviors trigger their seizures. The most common seizure precipitants are irregularities of sleep, sensory triggers such as flashing lights and emotional stress. Patients will learn how to avoid seizure precipitants and how to stop seizures in their first beginnings. Study participants will continue their prior medications.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 2 | No Intervention | Receives only EEG and questionnaire testing, no behavioral intervention or meditative relaxation | |
| 1 | Experimental | Andrews/Reiter behavioral treatment for epilepsy and EEG and questionnaire testing |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Andrews/Reiter behavioral treatment for epilepsy | Behavioral | The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises. |
| Measure | Description | Time Frame |
|---|---|---|
| Seizure frequency | At enrollment, end of 2-3 month baseline, after 6 months of treatment, and 6 months after end of treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Epileptiform EEG changes | At enrollment, end of 2-3 month baseline, after 6 months of treatment, and 6 months after end of treatment. | |
| Heartrate variability | At enrollment, end of 2-3 month baseline, after 6 months of treatment, and 6 months after end of treatment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Siegward M Elsas, M.D. | Oregon Health and Science University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oregon Health and Science University | Portland | Oregon | 97239 | United States |
Not provided
| ID | Term |
|---|---|
| D004828 | Epilepsies, Partial |
| ID | Term |
|---|---|
| D004827 | Epilepsy |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Salivary cortisol | At enrollment, end of 2-3 month baseline, after 6 months of treatment, and 6 months after end of treatment. |
| Questionnaires on stress, emotional well-being, self-efficacy, sleepiness and quality of life | At enrollment, end of 2-3 month baseline, after 6 months of treatment, and 6 months after end of treatment. |